SHARx: TrumpRx platform exposes issues in drug pricing and access

ST. LOUIS — The launch of the Trump administration’s TrumpRx drug pricing platform is increasing scrutiny of prescription drug costs, but industry experts say transparency alone might not solve the core barriers patients face in accessing medications.

According to SHARx, the main factors affecting patient affordability go beyond drug list prices to include the complex systems that handle coverage, approvals, and distribution. Pharmacy benefit managers (PBMs), which operate between drug manufacturers, insurers, and pharmacies, play a key role in determining what patients ultimately pay and whether they can get the prescribed treatments.

While TrumpRx seeks to lower costs by encouraging direct purchasing and greater pricing transparency, most Americans still get their medications through employer-sponsored insurance plans, where PBMs set coverage rules, reimbursement rates, and pharmacy networks.

Industry experts point out that these intermediaries control crucial decisions, including formulary placement, prior authorization requirements, and distribution channels. As a result, even insured patients may experience delays or restrictions when trying to access needed therapies.

“Coverage doesn’t always mean access,” said Paul Pruitt, chief growth officer of SHARx, noting that patients can encounter administrative hurdles such as step therapy and approval processes before beginning treatment.

The challenges are particularly pronounced in the specialty drug market, one of the fastest-growing segments of pharmaceutical spending. High-cost therapies for conditions such as cancer and autoimmune diseases are often subject to stricter utilization controls, including limited pharmacy networks and enhanced authorization requirements.

At the same time, increasing vertical integration across the healthcare system is raising additional concerns. Many large PBMs are now part of organizations that also own insurers and pharmacies, a structure critics say can create overlapping financial incentives and reduce transparency.

Employers, who provide health coverage for a majority of Americans, are also pushing for greater clarity. Rising drug costs and opaque rebate structures have made it difficult for plan sponsors to track spending and evaluate the true cost of medications.

SHARx argues that without addressing the rebate-driven economics and decision-making power embedded within the PBM system, efforts to reduce drug prices may have limited impact on patients.

As policymakers revisit drug pricing reform, the debate is shifting toward whether meaningful change requires not only price transparency but also structural changes to the systems that govern access to medications.

Learn more at: sharxplan.com